Ann: Notice of General Meeting/Proxy Form, page-129

First 129 Last

Share
Profile

Follow
naomhan

1,180 Posts.

1068

14/10/21

21:41

Post #: 56812163
Share

Originally posted by bluebird28: ↑

Pal, we are all posting for different reasons.
Winging and moaning about your investment in ISX is lost is what you have ruled out from day dot of suspension and have paraded day in day out on this forum. Reality check this will not influence the outcome either way
You or i do not represent or speak on behalf of the market... no one can.
But... one with logic has to be optimistic with the chain of events of the past 2 years and no i will not go through them line by line, combined with the strong potential of ISX growth in Europe.
The manner in which the market decided the valuation of ISX to a peak of $1.7 billion in 2019 in OZ, will be the same form of factors considered when listing in Europe by the Market.
JK is one of the strongest leaders i have seen from a tonne of companies based of the extreme malice intent of those entities, past leaders i have seen have thrown in the towel for a lot less ...if one cannot see this as a positive then i dont know what will.

FYI, others including myself have invested considerable amounts in ISX, alot more than the $15k, but a point to note, is that how we came to invest in that large amount is via success in investments in all works of life and allocate our precious commodity - time in an intelligent way to maximize our wealth.
You approach has alot to be questioned.

Expand

Never said I'd influence the outcome.

You admit we're all here for different reasons, but seem to think mine are invalid.

Vastly disagree with you on JK being a strong leader.

ISX Price at posting: $1.07 Sentiment: None Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome